Spotlight Stories

81. Platforms To Pipelines: Part 1 4/1/2022

    To discover why companies go about transforming themselves from technology suppliers into biotherapeutics developers, we spoke with the heads of five companies built upon novel platforms for discovery or development of new biotherapeutics, though at various stages and differences in applied strategies.

82. Art Of The Startup — Making New Waves 3/1/2022

    As Shoreline’s chairman, CEO, and cofounder, Dr. Kleanthis Xanthopoulos draws on his experience of several decades, starting and running companies that aim to overturn prevailing practices in areas of medicine where practice makes imperfect, with treatments that disappoint patients or prove expensive and impractical for many.

83. Tackling Uncertainty In Drug R&D 1/4/2022

    Can bioinformatics help biopharma companies manage their expectations and limit their risk in drug R&D? Ben Zeskind, a CEO who has built and bet his entire career on a positive answer to that question, discusses his reasons for optimism.

84. Can the FDA & CDC Recover from Recent Politics? 12/1/2021

    Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.

85. Long Hauler In The Antibiotics Space 11/1/2021

    For Ted Schroeder, CEO of Nabriva Therapeutics, the road of his biopharma career led him into the antibiotics space, a mighty steep climb in the biopharma industry.

86. Going Precommercial — From The Commercial World 10/1/2021

    Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”

87. VCs Breathe New Life Into Life Sciences Industrials 9/1/2021

    The “industrials” or supplier sector of the biopharma industry, in a significant change from the past, is now receiving an extra financial boost from VC funding. Why should their biopharma customers care?

88. Coming Out Of Stealth Mode: What To Know And Do 8/2/2021

    In Part two of this two-part series, we look at what companies should do to make the exit from stealth mode an effective exchange with the outside world — how to identify and reach investors, influencers, and stakeholders in a company’s pursuit of new treatments for diseases, from rare conditions to widespread medical challenges, some at the scale of public health.

89. The Collective Benefits Of A Collaborative CFO 7/1/2021

    Terry Coelho, CFO, works as a team member, not just a finance manager, at BioDelivery Sciences.

90. Coming Out Of Stealth Mode: What To Know And Do 7/1/2021

    Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.